Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5-azacitidine + tretinoin
- Development stage
- Unknown
- Lead developer
- Icahn School of Medicine
- Modality
- Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
5-azacitidine + tretinoin is a combination therapy being investigated by the Icahn School of Medicine at Mount Sinai for the treatment of biochemically recurrent prostate cancer. The regimen consists of 5-azacitidine (5-AZA), a DNA methyltransferase inhibitor, and all-trans retinoic acid (ATRA, also known as tretinoin), a retinoic acid receptor (RAR) agonist. This combination is designed as a 'reprogramming therapy' to induce tumor cell dormancy in disseminated cancer cells. By inhibiting DNA methylation and activating retinoic acid signaling, the treatment aims to restore the TGF-β-SMAD4 signaling pathway and induce dormancy-regulating genes, such as NR2F1. The clinical goal is to delay disease progression and prolong PSA doubling time in patients with rising PSA levels after definitive local treatment, potentially avoiding or delaying the need for androgen deprivation therapy.
- Other names
- 5-azacitidine + all-trans retinoic acidall-trans retinoic acid + 5-azacitidineATRA + 5-AZA
02
Targets
DNMT1 (DNA (cytosine-5)-methyltransferase 1)RARA (Retinoic acid receptor alpha)RARG (Retinoic acid receptor gamma)RARB (Retinoic acid receptor beta)
Beyond the preview
Go deeper on 5-azacitidine + tretinoin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 5-azacitidine + tretinoin.